This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Surging Earnings Estimates Signal Good News for West Pharmaceutical (WST)
by Zacks Equity Research
West Pharmaceutical (WST) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
CVS Health (CVS) Q2 Earnings Top Estimates, 2020 View Up
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits segment registers membership growth in Q2.
Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates
by Zacks Equity Research
Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.
Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.
Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.
AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter earnings benefit from segmental growth.
QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up
by Zacks Equity Research
QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.
Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract
by Zacks Equity Research
Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.
Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.
Henry Schein (HSIC) Q2 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.
The Zacks Analyst Blog Highlights: PulteGroup, Quidel, D.R. Horton and West Pharmaceutical Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PulteGroup, Quidel, D.R. Horton and West Pharmaceutical Services
LabCorp (LH) Banks on Covance Amid Testing Volume Pressure
by Zacks Equity Research
LabCorp's (LH) COVID-19 related research too has been progressing well.
Bet on These 5 Low Leverage Stocks This Earnings Season
by Zacks Equity Research
Debt is something that gives you the chills since it brings with it the burden of repayment with additional interest in the future. So investors should choose stocks prudently
McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2021 results benefit from strong U.S. Pharmaceutical and Specialty Solutions segment.
Hill-Rom's (HRC) Q3 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) benefits from increased demand for critical care products due to the coronavirus outbreak.
Wall Street is Northbound Defying All Concerns: 5 Top Picks
by Nalak Das
A new bull market that was developed last quarter exiting the coronavirus-induced short bear market, is raging forward in the third quarter too.
IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise
by Zacks Equity Research
IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.
Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract
by Zacks Equity Research
Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.
Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.
Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises
by Zacks Equity Research
Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.
Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
Integer Holdings (ITGR) Q2 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect from weak segmental performance and margin contraction.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect weak segmental performance.
OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from increase in RAYALDEE prescriptions.